Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179036 | 1.00 | HTR2C (0.54) | HTR2CCHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL468999 | 0.95 | MEN1 (0.54) | HTR2CCHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL172484 | 0.87 | HTR2C (0.59) | HTR2CCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL28524487 | 0.81 | CHRNB2 (0.56) | HTR2CCHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL28524486 | 0.81 | CHRNB2 (0.56) | HTR2CCHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL29855657 | 0.81 | CHRNB2 (0.56) | HTR2CCHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL28526307 | 0.81 | CHRNB2 (0.56) | HTR2CCHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL25395851 | 0.81 | CHRM2 (0.46) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL2676473 | 0.81 | CHRM2 (0.46) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL30689237 | 0.81 | CHRM2 (0.46) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-03 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-12286406-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-118684696-A | Fluorine-containing probe molecules for chiral analysis | 中国科学院上海有机化学研究所 | 2024-09-24 | — | — | CN | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-115605463-B | Inhibitors of receptor-interacting protein kinase I for the treatment of diseases | 德州大学系统董事会 | 2024-08-09 | — | — | CN | disclosed |
| EP-3715342-B1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHONGHONGXIN INVEST HOLDINGS SHENZHEN CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-0926164-B1 | Substituted amino silane compounds and catalyst for the polymerization of alpha-olefins containing them | BASELL NORTH AMERICA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| US-6130180-A | Catalyst for the polymerization of alpha-olefins containing substituted amino silane compounds | MONTELL NORTH AMERICA INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| EP-0926164-A2 | Substituted amino silane compounds and catalyst for the polymerization of alpha-olefins containing them | MONTELL NORTH AMERICA INC. (US) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | HTR2C 3753/4885CHRNB2 1932/4885CHRNA7 1861/4885 |
| US-12286406-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | HTR2C 3753/4885CHRNB2 1932/4885CHRNA7 1861/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | HTR2C 3764/4885CHRNB2 4503/4885CHRNA7 4831/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | HTR2C 3764/4885CHRNB2 4503/4885CHRNA7 4831/4885 |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | HTR2C 3753/4885CHRNB2 1932/4885CHRNA7 1861/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | HTR2C 773/4885CHRNB2 469/4885CHRNA7 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.